1. Pink Sheet
  2. >>Compliance

Reimbursement Support Programs Create 'Holy Trinity' Of Enforcement Risk

 
• By Sue Sutter

Services that help doctors' offices navigate payment hurdles could draw government scrutiny for false claims, kickbacks, and medical privacy violations, attorney says.

BusinessmanBehindBars_1200-x-675

Drug manufacturer programs that help health care providers navigate reimbursement hurdles carry potential compliance risks and are of growing interest to government investigators, an industry attorney said.

Reimbursement assistance programs represent the "holy trinity" of enforcement risks, with the potential for violations under the federal False Claims...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

FY 2025 Generic Drugs By The Numbers

 
• By Derrick Gingery

New FDA data shows a potentially concerning drop in ANDA submissions, while the first-cycle approval rate increased.

Pfizer’s Advertising Challenge Against BridgeBio’s Attruby Leverages US FDA Untitled Letter

 
• By Sue Sutter

Pfizer, which markets Vyndamax for transthyretin amyloid cardiomyopathy, said an FDA violation letter shows BridgeBio made false and misleading superiority claims, but BridgeBio refused to participate in the National Advertising Division process.

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

More from Pink Sheet

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation

 
• By Neena Brizmohun

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.

Sponsored by

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.